Answers are grounded in this paper and cite their sources.
Type 2 diabetes (T2D) and its related neurodegenerative complications greatly pose a serious health and economic burden. In recent years, neurofilament light (NfL) has been proved to be as a biomarker of neurodegeneration, and the levels of plasma NfL were found to be associated with clinical staging of diabetes mellitus and cognitive decline. In this review, we indicate that the level of NfL in blood may be a valuable clinical tool to distinguish the normal population, pre-diabetes and diabetes patients. In addition, NfL levels of diabetic patients are closely related to diabetic complications, such as diabetic distal symmetric polyneuropathy, diabetic nephropathy and cardiovascular and cerebrovascular diseases. Furthermore, NfL levels of diabetic patients is also correlated with Alzheimer's disease, Parkinson's disease and COVID-19. Therefore, the level of NfL in blood may be a valuable clinical tool to distinguish the normal population, pre-diabetes and diabetes patients, to identify mild cognitive decline in diabetes patients.
No takes yet. Share an insight, caveat, or question.
Tian et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: